AssetMark’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding AVTX
AssetMark's AVTX Position: Q3 2026 in Review
AssetMark held its Avalo Therapeutics (AVTX) position steady in Q3 2026 at 22 shares worth $337. The position accounts for ﹤0.01% of the portfolio, ranked #3519.
AssetMark first reported a position in AVTX in Q2 2026 and has held it in 2 quarters since. The position peaked at $407 in Q2 2026. 88 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.
- AssetMark held 22 shares of Avalo Therapeutics worth $337 as of Q3 2026.
- AssetMark left its Avalo Therapeutics share count unchanged in Q3 2026.
- Avalo Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3519 holding.
- AssetMark first reported a position in Avalo Therapeutics in Q2 2026 and has held it in 2 quarters since.
- AssetMark's Avalo Therapeutics position peaked at $407 in Q2 2026.
- 88 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.